Supported in part by National Institutes of Health/National Eye Institute Grants EY021818 (FAM), EY11008 (LMZ), EY14267 (LMZ); Brazilian National Research Council-CNPq Grant 200178/2012-1 (DM-F); an unrestricted grant from Research to Prevent Blindness (New York, New York); and grants for participants' glaucoma medications from Alcon, Allergan, Pfizer, Merck, and Santen.
Disclosure: D. Meira-Freitas, None; R. Lisboa, None; A. Tatham, None; L.M. Zangwill, Carl-Zeiss Meditec, Inc. (F), Heidelberg Engineering (F); R.N. Weinreb, Carl-Zeiss Meditec, Inc. (F, C), Alcon (F), Allergan (F), Merck (F), Bausch & Lomb (F), Optovue (F), Novartis (F), Nidek (F, R), Topcon (F, R), Aeries (F); C.A. Girkin, Carl-Zeiss Meditec, Inc. (F); J.M. Liebmann, Carl-Zeiss Meditec, Inc. (F), Heidelberg Engineering (F); F.A. Medeiros, Carl-Zeiss Meditec, Inc. (F), Heidelberg Engineering (F), Alcon (F), Allergan (F), Merck (F), Bausch & Lomb (F), Nidek (F), P